About Me

I am a urologic surgeon with expertise in the treatment of urologic tumors — which include bladder, urethral, and kidney cancers. I am currently heading clinical trials at Memorial Sloan Kettering to evaluate new therapies for the treatment of high-risk superficial bladder cancer in patients who are resistant to bacillus Calmette-Guérin (BCG) therapy, the standard treatment. I also have expertise in nerve-sparing radical cystectomy followed by bladder reconstruction. I have written a number of articles, and I am on the editorial boards of and a reviewer for several peer-reviewed journals.

Read more
  • Clinical Expertise: Bladder Cancer; Upper Tract; Urologic Oncology; Kidney Cancer
  • Languages Spoken: English
  • Education: MD, Cairo University Faculty of Medicine (Egypt); MD, University of Parma (Italy)
  • Residencies: Cabrini Medical Center (New York), New York University Medical Center
  • Fellowships: Memorial Sloan Kettering Cancer Center
  • Board Certifications: Urology

New Patient Appointments

Making an appointment

Call 646-497-9068

See My Colleagues

Read more

Dalbagni G, Russo P, Sheinfeld J, Mazumdar M, Tong W, Rabbani F, Donat MS, Herr HW, Sogani P, dePalma D, Bajorin D. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder.. J Clin Oncol. 2002; 20(15) :3193-8

Dalbagni G, Herr HW, Reuter VE. Impact of a second transurethral resection on the staging of T1 bladder cancer.. Urology 2002; 60(5) :824-825

Dalbagni G, Donat SM, Eschwege P, Herr HW, Zelefsky MJ. Results of high-dose brachytherapy (HDR-BRT), anterior pelvic exenteration and external beam radiotherapy for carcinoma of the female urethra. J Urol 2001; 166 :1759-1761

Dalbagni G, Ren Z-P, Herr HW, Cordon-Cardo C, Reuter VE. Genetic alterations in TP53 in recurrent urothelial cancer: A longitudinal study. CI Cancer Res 2001; 7 :1797-2801

Dalbagni G, Genega E, Hashibe M, Zhang Z-F, Russo P, Herr HW, Reuter V. Cystectomy for Bladder Cancer: A Contemporary Series. J Urol 2001; 165 :1111-1116

Cozzi PJ, Bajorin DF, Tong W, Nguyen H, Scott J, Heston WDW, Dalbagni G. Toxicology and Pharmacokinetics of Intravesical Gemcitabine: A Preclinical Study in Dogs. CI Cancer Res 1999; 5 :2629-2637

Dalbagni G, Reschtschaffen T, Herr HW. Is Transurethral Biopsy of the Bladder Necessary After 3 Months to Evaluate Response to BCG Therapy. J Urol 1999; 162 :708-709

Dalbagni G, Zhang Z-F, Lacombe L, Herr HW. Male Urethral Carcinoma: Analysis of Treatment Outcome. Urology 1999; 53 :1126-1132

Dalbagni G, Zhang Z-F, Lacombe L, Herr HW. Female Urethral Carcinoma: Analysis of treatment outcome and a plea for a standardized management strategy. Br J Urol 1998; 82 :835-841

Visit PubMed for a full listing of Guido Dalbagni’s journal articles

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.

Clinical Trials

As home to one of the world’s top cancer research centers, Memorial Sloan Kettering is typically involved in more than 900 clinical trials at a given time. Currently, clinical trials focused on the conditions I treat are enrolling new patients. If you’re interested in joining a clinical trial, click to learn about the trial’s purpose, eligibility criteria, and how to get more information.

Learn more


Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.

Learn more